- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- F-1 Registration statement (foreign)
- 3.1 Second Amended and Restated Memorandum and Articles of Association of Aptorum Group Limited
- 4.1 Specimen Ordinary Share Certificate
- 4.2 Form of Series a Convertible Promissory Note
- 10.1 Appointment Letter Between the Company and Ian Huen (Founder, Chief Executive Officer & Executive Director), Dated September 25, 2017
- 10.2 Employment Letter Between the Company and Sabrina Khan (Chief Financial Officer), Dated September 1, 2017
- 10.3 Addendum to Employment Letter Between Company and Sabrina Khan (Chief Financial Officer) Dated April 24, 2018
- 10.4 Appointment Letter Between the Company and Darren Lui (Chief Business Officer, President & Director), Dated September 25, 2017
- 10.5 Employment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated August 31, 2017
- 10.6 Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated September 25, 2017
- 10.7 Second Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated October 30, 2017
- 10.8 Third Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated January 2, 2018
- 10.9 Appointment Letter Between the Company and Keith Chan (Chief Scientific Officer), Dated August 18, 2017
- 10.10 Appointment Letter Between the Company and Charles Bathurst (Independent Non-executive Director), Dated September 24, 2017
- 10.11 Appointment Letter Between the Company and Mirko Scherer (Independent Non-executive Director), Dated September 24, 2017
- 10.12 Employment Agreement Between the Company and Justin Wu (Independent Non-executive Director), Dated September 18, 2017
- 10.13 Employment Agreement Between the Company and Douglas Arner (Independent Non-executive Director), Dated February 13, 2018
- 10.14 Management Agreement Between the Company and Guardian Capital Management Limited, Dated March 1, 2017
- 10.15 Consulting Agreement Between the Company and Globoasia, LLC (Includes Provisions for the Appointment of Keith Chan As Chief Scientific Officer) Dated August 18, 2017
- 10.16 Management Agreement Between the Company and Aptus Capital Limited, Dated October 26, 2010
- 10.17 First Addendum to the Management Agreement Between the Company and Aptus Capital Limited, Dated February 10, 2012
- 10.18 Second Addendum to the Management Agreement Between the Company and Aptus Capital Limited, December 9, 2016
- 10.19 Subscription Agreement Between the Company and Peace Range Limited, Dated April 6, 2018
- 10.20 Share Charge Agreement Between the Company, Jurchen Investment Corporation and Peace Range Limited, Dated April 25, 2018
- 10.21 Deed of Guarantee of Jurchen Investment Corporation, Acknowledged by Peace Range Limited, Dated April 25, 2018
- 10.22 Charge Account Agreement Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.23 Bond Certificate Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.24 Escrow Agreement Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.25 2017 Share Option Plan
- 10.26 Form of Securities Purchase Agreement for the Series a Convertible Promissory Notes, Dated May 15, 2018
- 10.27 Lock-up Agreement for Series a Convertible Promissory Notes, Dated May 15, 2018
- 10.28 Exclusive License Agreement for NLS-1 Dated July 3, 2017
- 10.29 Addendum to License Agreement for NLS-1 Dated February 9, 2018
- 10.30 Exclusive Patent License Agreement for ALS-1
- 10.31 First Amendment to the Exclusive Patent License Agreement for ALS-1 Dated June 7, 2018
- 10.32 Exclusive Patent License Agreement for ALS-4
- 10.33 First Amendment to the Exclusive Patent License Agreement Dated June 7, 2018
- 10.34 Sub-tenancy Agreement for Guangdong Investment Tower
- 10.35 Service Agreement Between Covar Pharmaceuticals Incorporated and Videns Incorporation Limited Dated May 15, 2017
- 10.36 Appointment Letter and Addendum to Service Agreement with Covar Pharmaceuticals Incorporated and DR. Kwok Chow Dated December 15, 2017
- 10.37 Appointment Letter and Addendum to Service Agreement with Covar Pharmaceuticals Incorporated and MR. Austin Freedman Dated December 26, 2017
- 14.1 Code of Business Conduct and Ethics of the Company
- 21.1 List of Subsidiaries
- 23.1 Consent of Marcum Bernstein & Pinchuk LLP
- 99.1 Charter of the Audit Committee
- 99.2 Charter of the Compensation Committee
- 99.3 Charter of the Nominating and Corporate Governance Committee
Exhibit 10.8
APTUS Management Limited
17/F Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong
Tel: (852) 2117 6611 ● Fax: (852) 2850 7286
2 January 2018
Dr. Clark Cheng
Present
Dear Clark,
Addendum to Employment Letter (the “Addendum”)
This letter supplements and serves to be an addendum to the Employment Letter dated 31st August 2017 (“Employment Letter”) executed between yourself and APTUS Management Limited (the “Company”) in relation to your employment as Executive Director and Chief Medical Officer of Aptorum Group Limited and Executive Director of Aptorum Medical Limited. This Addendum should be read together with, and forms part of, the Employment Letter.
This Addendum serves to describe the following amendments and/or additions to the Employment Letter.
i. | Date of Commencement |
Pursuant to Clause 3 of Employment Letter, the official commencement date of your employment shall be on2 January 2018 (the “Effective Date”).
Please signify your acceptance of the above amendment described in this Addendum by signing and returning to us the enclosed duplicate copy of this letter.
Yours faithfully, | ||
For and on behalf of | ||
APTUS MANAGEMENT LIMITED | Agreed and accepted by: | |
Huen Chung Yuen Ian | Cheng Clark | |
Director | HKID No. Z243983(3) |